Antimicrobial Synergy Testing : Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived
| dc.contributor.author | Okoliegbe, Ijeoma N. | |
| dc.contributor.author | Hijazi, Karolin | |
| dc.contributor.author | Cooper, Kim | |
| dc.contributor.author | Ironside, Corinne | |
| dc.contributor.author | Gould, Ian M | |
| dc.contributor.institution | University of Aberdeen.Dental Education | en |
| dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
| dc.date.accessioned | 2021-08-13T10:53:01Z | |
| dc.date.available | 2021-08-13T10:53:01Z | |
| dc.date.issued | 2021-08-12 | |
| dc.description | Funding: This research was funded by the NHS Grampian Endowment fund, grant number EA9431, and the NHS Grampian Clinical Microbiology Fund (NHS Grampian Endowment Funds, Registered Charity Number SC017296). Acknowledgments: The authors would like to thank the laboratories and clinicians who use the Cystic Fibrosis Susceptibility Testing Service. CFASS is an adult patient-testing facility, funded by the National Services Division of the Common Services Agency of the Scottish Executive. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 12 | |
| dc.format.extent | 925226 | |
| dc.identifier | 198420491 | |
| dc.identifier | 29532e3a-2dfa-4ee8-910d-fe16bffe8e8a | |
| dc.identifier | 85113761255 | |
| dc.identifier | 000688660900001 | |
| dc.identifier.citation | Okoliegbe, I N, Hijazi, K, Cooper, K, Ironside, C & Gould, I M 2021, 'Antimicrobial Synergy Testing : Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived', Antibiotics, vol. 10, no. 8, 967. https://doi.org/10.3390/antibiotics10080967 | en |
| dc.identifier.doi | 10.3390/antibiotics10080967 | |
| dc.identifier.iss | 8 | en |
| dc.identifier.issn | 2079-6382 | |
| dc.identifier.uri | https://hdl.handle.net/2164/16945 | |
| dc.identifier.vol | 10 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Antibiotics | en |
| dc.subject | antimicrobials | en |
| dc.subject | ceftazidime | en |
| dc.subject | combination antimicrobial susceptibility testing | en |
| dc.subject | gradient diffusion | en |
| dc.subject | Pseudomonas aeruginosa | en |
| dc.subject | synergy testing | en |
| dc.subject | tobramycin | en |
| dc.subject | R Medicine | en |
| dc.subject | RK Dentistry | en |
| dc.subject | Other | en |
| dc.subject | EA9431 | en |
| dc.subject | Supplementary Information | en |
| dc.subject.lcc | R | en |
| dc.subject.lcc | RK | en |
| dc.title | Antimicrobial Synergy Testing : Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Okoliegbe_etal_MDPI_Antimicrobial_Synergy_Testing_VoR.pdf
- Size:
- 903.54 KB
- Format:
- Adobe Portable Document Format
